Pfizer (PFE) - Investment Analysts' Recent Ratings Updates
They now have a "buy" rating on the stock. 10/18/2016 - Pfizer had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
from Biotech News
They now have a "buy" rating on the stock. 10/18/2016 - Pfizer had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments